What is claimed is:

1. A siRNA for inhibiting AGT gene expression, wherein the siRNA comprises a sense strand and an antisense strand; wherein, the antisense strand comprises the SEQ ID NO: 105 (5'-UUCAUUAGAAGAAAAGGUGGUU-3'); the sense strand comprises the SEQ ID NO:23 (5'-CCACCUUUUCUUCUAAUGAA-3').

2. The siRNA according to claim 1, wherein all nucleotides in the sense strand and/or the antisense strand of the siRNA are modified nucleotides or nucleotide analogs.

3. The siRNA according to claim 2, wherein the modified nucleotide is selected from the group consisting of 2'-methoxynucleotides, 2'-fluoronucleotides, 2'-deoxynucleotides, 2',3'-seco-nucleotide analogs, 2'-fluoroarabinonucleotides, 2'-methoxyethylnucleotides, 2'-amino-modified nucleotides, 2'-alkyl-modified nucleotides, 3'-methoxynucleotides, 2'-allyl-modified nucleotides, phosphorothioate group-containing nucleotides, methylphosphonate group-containing nucleotides, 5'-phosphate group-containing nucleotides, 5'-phosphate mimic-containing nucleotides, diol-modified nucleotides, abasic nucleotides, morpholinonucleotides, locked nucleotides, unlocked nucleotides, threose nucleotides, and glycerol nucleotides.

4. The siRNA according to any one of claims 1 to 3, wherein the 5' end and 3' end of the sense strand each independently comprise 0, 1, or 2 phosphorothioate linkages; and/or the 5' end and 3' end of the antisense strand each independently comprise1 or 2 phosphorothioate linkages.

5. The siRNA according to any one of claims 1 to 4, wherein the first nucleotide at the 5' end of the antisense strand is a (*E*)-vinylphosphate-modified nucleotide.

6. The siRNA according to any one of claims 1 to 5, wherein

the antisense strand of the siRNA is 22 nucleotides in length, wherein 3-10 positions (e.g., positions 2, 14, 16; positions 2, 5, 14, 16; positions 2, 6, 14, 16; positions 2, 4, 6, 14, 16; positions 2, 6, 10, 14, 16; positions 2, 6, 12, 14, 16; positions 2, 5, 10, 14, 16; positions 2, 3, 12, 14, 16; positions 2, 9, 12, 14, 16; positions 2, 6, 8, 9, 14, 16; positions 2, 3, 5, 12, 14, 16; positions 2, 8, 9, 12, 14, 16; positions 2, 7, 9, 12, 14, 16; positions 2, 4, 6, 8, 10, 14, 16, 18, 20; positions 2, 4, 5, 6, 8, 10, 12, 14, 16, 18 at the 5' end) of the antisense strand are2'-fluoronucleotides, and the remaining positions are 2'-methoxynucleotides,

the sense strand of the siRNA is 20 nucleotides in length, wherein positions 8, 9, and 10 at the 5' end of the sense strand are 2'-fluoronucleotides, optionally one position (preferably position 1 at the 5' end) is a threose nucleotide, optionally one position (preferably position 6 at the 5' end) is a 2'-deoxynucleotide, and the remaining positions are 2'-methoxynucleotide conjugates;

preferably, the antisense strand of the siRNA is 22 nucleotides in length, wherein the following positions: positions 2, 14, 16; or positions 2, 5, 14, 16; or positions 2, 6, 14, 16; or positions 2, 4, 6, 14, 16; or positions 2, 6, 10, 14, 16; or positions 2, 6, 12, 14, 16; or positions 2, 5, 10, 14, 16; or positions 2, 3, 12, 14, 16; or positions 2, 9, 12, 14, 16; or positions 2, 6, 8, 9, 14, 16; or positions 2, 3, 5, 12, 14, 16; or positions 2, 8, 9, 12, 14, 16; or positions 2, 7, 9, 12, 14, 16; or positions 2, 4, 6, 8, 10, 14, 16, 18, 20; or positions 2, 4, 5, 6, 8, 10, 12, 14, 16, 18, at the 5' end of the antisense strand are 2'-fluoronucleotides, and the remaining positions are 2'-methoxynucleotides,

the sense strand of the siRNA is 20 nucleotides in length, wherein positions 8, 9, and 10 at the 5' end of the sense strand are 2'-fluoronucleotides, optionally, position 1 at the 5' end is a threose nucleotide, or optionally, position 6 at the 5' end is a 2'-deoxynucleotide, and the remaining positions are 2'-methoxynucleotides;

preferably, the 2'-deoxynucleotide at position 6 is independently selected from the group consisting of deoxyadenosine monophosphate (dA), deoxyguanosine monophosphate (dG), deoxycytidine monophosphate (dC), deoxythymidine monophosphate (dT), deoxyuridine

monophosphate (dU); more preferably, the 2'-deoxynucleotide at position 6 is deoxythymidine monophosphate (dT);

more preferably, the antisense strand of the siRNA is 22 nucleotides in length, wherein the following positions: positions 2, 14, 16; or positions 2, 5, 14, 16; or positions 2, 6, 14, 16; or positions 2, 4, 6, 14, 16; or positions 2, 6, 10, 14, 16; or positions 2, 6, 12, 14, 16; or positions 2, 5, 10, 14, 16; or positions 2, 3, 12, 14, 16; or positions 2, 9, 12, 14, 16; or positions 2, 6, 8, 9, 14, 16; or positions 2, 3, 5, 12, 14, 16; or positions 2, 8, 9, 12, 14, 16; or positions 2, 7, 9, 12, 14, 16; or positions 2, 4, 6, 8, 10, 14, 16, 18, 20; or positions 2, 4, 5, 6, 8, 10, 12, 14, 16, 18, at the 5' end of the antisense strand are 2'-fluoronucleotides, and the remaining positions are 2'-methoxynucleotides; the sense strand of the siRNA is 20 nucleotides in length, wherein positions 8, 9, 10 at the 5' end of the sense strand are 2'-fluoronucleotides, and the remaining positions are 2'-methoxynucleotides; or

the antisense strand of the siRNA is 22 nucleotides in length, wherein positions 2, 6, 14, 16 at the 5' end of the antisense strand are 2'-fluoronucleotides, and the remaining positions are 2'-methoxynucleotides; the sense strand of the siRNA is 20 nucleotides in length, wherein positions 8, 9, and 10 at the 5' end of the sense strand are 2'-fluoronucleotides, position 1 is a threose nucleotide, and the remaining positions are 2'-methoxynucleotides; or

the antisense strand of the siRNA is 22 nucleotides in length, wherein positions 2, 6, 14, 16 at the 5' end of the antisense strand are 2'-fluoronucleotides, and the remaining positions are 2'-methoxynucleotides; the sense strand of the siRNA is 20 nucleotides in length, wherein positions 8, 9, 10 at the 5' end of the sense strand are 2'-fluoronucleotides, position 6 is a 2'-deoxynucleotide, and the remaining positions are 2'-methoxynucleotides; preferably, the 2'-deoxynucleotide at position 6 is independently selected from the group consisting of deoxyadenosine monophosphate (dA), deoxyguanosine monophosphate (dG), deoxycytidine monophosphate (dC), deoxythymidine monophosphate (dT), deoxyuridine monophosphate (dU); more preferably, the 2'-deoxynucleotide at position 6 is deoxythymidine monophosphate (dT);

more preferably, the antisense strand of the siRNA is the nucleotide sequence as set forth in SEQ ID NO: 105 (5'-UUCAUUAGAAGAAAAGGUGGUU-3'), and the sense strand of the siRNA is the nucleotide sequence as set forth in SEQ ID NO: 23 (5'-CCACCUUUUCUUCUAAUGAA-3').

7. The siRNA according to claim 6, wherein the first nucleotide at the 5' end of the antisense strand is a (*E*)-vinylphosphate-modified nucleotide.

8. The siRNA according to any one of claims 6 to 7, wherein the 3' end and/or 5' end of the sense strand each are attached to an inverted abasic residue (iab), preferably the 3' end and 5' end of the sense strand each are attached to an inverted abasic residue (iab).

9. An siRNA conjugate, which is obtained by conjugating the siRNA according to any one of claims 1 to 8 with a conjugating molecule.

10. The siRNA conjugate according to claim 9, wherein the conjugating molecule is derived from a delivery carrier moiety via a covalent bond, and is independently or simultaneously linked to the 3' or 5' end of the sense strand of the siRNA.

11. The siRNA conjugate according to claim 10, wherein the delivery carrier moiety is selected from the group consisting of: GalNAc(L96), Ser(GN), GalNAc(Ser1), GalNAc(Ser2), GalNAc(Ser3), GalNAc(Ser4), LP-GalNAc, XY-GalNAc, GalNAc(A1GN), GalNAc(A2GN), GalNAc(A3GN), GalNAc(A4GN), GalNAc(A5GN), GAlNAc(NAG25), and GAlNAc(NAG37),

wherein,

GalNAc(L96) has the following structure:



,



Ser(GN) has the following structure: ;

GalNAc(Ser1), GalNAc(Ser2), GalNAc(Ser3), GalNAc(Ser4) have the following structures, respectively:



GalNAc(Ser1)

,



X= OH, SH

GalNAc(Ser2)

,



X= OH, SH

GalNAc(Ser3)

,



X= OH, SH

GalNAc(Ser4)

,

LP-GalNAc has the following structure:



,

XY-GalNAc has the following structure:



or



,

GalNAc(A1GN), GalNAc(A2GN), GalNAc(A3GN), GalNAc(A4GN), GalNAc(A5GN), GAlNAc(NAG25), and GAlNAc(NAG37) have the following structures, respectively:



GalNAc(A1GN)



GalNAc(A2GN)



GalNAc(A3GN)



GalNAc(A4GN)



GalNAc(A5GN)



GalNAc(NAG25)



GalNAc(NAG37)

,

optionally, the above delivery carrier moiety is attached to the 3' end of the siRNA's sense strand, or to the 5' end of the siRNA's sense strand, or to an inverted abasic residue (iab) at the 3' end of the siRNA's sense strand, or to an inverted abasic residue (iab) at the 5' end of the siRNA's sense strand, or one or more of the above delivery carrier moieties are simultaneously attached to the 3' end of the siRNA's sense strand, the 5' end of the siRNA's sense strand, the inverted abasic residue (iab) at the 3' end of the siRNA's sense strand, or the inverted abasic residue (iab) at the 5' end of the siRNA's sense strand; preferably, the delivery carrier moiety GalNAc(L96) is attached to the 3' end of the siRNA's sense strand or to the inverted abasic residue (iab) at the 3' end of the siRNA's sense strand, the delivery carrier moiety Ser (GN) is simultaneously attached to the 3' end and the 5' end of the siRNA's sense strand, the delivery carrier moiety LP-GalNAc is attached to the 5' end of the siRNA's sense strand, the delivery carrier moiety XY-GalNAc is attached to the 3' end of the siRNA's sense strand, the delivery carrier moiety GalNAc(Ser2) is attached to the 3' end of the siRNA's sense strand or to the 5' end of the siRNA's sense strand or simultaneously to the 3' end and the 5' end of the siRNA's sense strand, the delivery carrier moiety GalNAc(Ser3) is attached to the 3' end of the siRNA's sense strand or to the 5' end of the siRNA's sense strand, the delivery carrier moiety GalNAc(Ser4) is attached to the 3' end of the siRNA's sense strand, the delivery carrier moiety GalNAc(A1GN) is attached to the 3' end of the siRNA's sense strand, the delivery carrier moiety GalNAc(A2GN) is attached to the 3' end of the siRNA's sense strand, the delivery carrier moiety GalNAc(A3GN) is attached to the 5' end of the siRNA's sense strand, the delivery carrier moiety GalNAc(A4GN) is attached to the 5' end of the siRNA's sense strand, the delivery carrier moiety GalNAc(A5GN) is attached to the 5' end of the siRNA's sense strand, the delivery carrier moiety GalNAc(NAG25) is attached to the 5' end of the siRNA's sense strand, the delivery carrier moiety GalNAc(NAG37) is attached to the 5' end of the siRNA's sense strand, and the delivery carrier moieties GalNAc(Ser1) and GalNAc(Ser2) are simultaneously attached to the 3' end and

5' end of the siRNA's sense strand, respectively, or simultaneously attached to the 5' end and 3' end of the siRNA's sense strand, respectively;

preferably, the delivery carrier moiety is selected from the group consisting of: GalNAc(L96) attached to the 3' end of the siRNA's sense strand, GalNAc(A1GN) attached to the 3' end of the siRNA's sense strand, GalNAc(A2GN) attached to the 3' end of the siRNA's sense strand, GalNAc(A3GN) attached to the 5' end of the siRNA's sense strand, GalNAc(A4GN) attached to the 5' end of the siRNA's sense strand, and GalNAc(Ser2) simultaneously attached to both the 3' and 5' ends of the siRNA's antisense strand.

12. The siRNA conjugate according to any one of claims 9 to 11, wherein the siRNA conjugate is selected from Conjugates 100, 102, 106, 161, 162, 163, 1633, 1634, 1637,1638 and 1642

No.	**Type**	**Sequence (5'→3')**
Conjugate 100	Sense strand	mC*mC*mAmCmCmUmUfUfUfCmUmUmCmUmAmAmU mGmAmA*GalNAc(L96)
	Antisense strand	eVPmU*fU*mCmAmUfUmAmGmAmAmGmAmAfAmAfG mGmUmGmG*mU*mU
Conjugate 102	Sense strand	mC*mC*mAmCmCmUmUfUfUfCmUmUmCmUmAmAmU mGmAmA*GalNAc(L96)
	Antisense strand	eVPmU*fU*mCmAmUmUmAmGmAmAmGmAmAfAmAf GmGmUmGmG*mU*mU
Conjugate 106	Sense strand	mC*mC*mAmCmCdTmUfUfUfCmUmUmCmUmAmAmUm GmAmA*GalNAc(L96)
	Antisense strand	eVPmU*fU*mCmAmUfUmAmGmAmAmGmAmAfAmAfG mGmUmGmG*mU*mU
Conjugate 161	Sense strand	iab*mC*mUmCmCmCmAmCfCfUfUmUmUmCmUmUmCm UmAmAmA*iabGalNAc(L96)
	Antisense strand	eVPmU*fU*mUmAmGfAmAmGmAmAmAmAmGfGmUfG mGmGmAmG*mU*mU
Conjugate 162	Sense strand	iab*mC*mCmAmCmCmUmUfUfUfCmUmUmCmUmAmA mUmGmAmA*iabGalNAc(L96)
	Antisense strand	eVPmU*fU*mCmAmUfUmAmGmAmAmGmAmAfAmAfG mGmUmGmG*mU*mU
Conjugate 163	Sense strand	iab*mC*mCmAmCmCmUmUfUfUfCmUmUmCmUmAmA mUmGmAmA*iabGalNAc(L96)
	Antisense strand	eVPmU*fU*mCmAmUmUmAmGmAmAmGmAmAfAmAf GmGmUmGmG*mU*mU

Conjugate 1633	Sense strand	mC*mC*mAmCmCmUmUfUfUfCmUmUmCmUmAmAmU mGmAmA*GalNAc(A1GN)
	Antisense strand	eVPmU*fU*mCmAmUfUmAmGmAmAmGmAmAfAmAfG mGmUmGmG*mU*mU
Conjugate 1634	Sense strand	mC*mC*mAmCmCmUmUfUfUfCmUmUmCmUmAmAmU mGmAmA*GalNAc(A2GN)
	Antisense strand	eVPmU*fU*mCmAmUfUmAmGmAmAmGmAmAfAmAfG mGmUmGmG*mU*mU
Conjugate 1637	Sense strand	GalNAc(A3GN)*mC*mCmAmCmCmUmUfUfUfCmUmUm CmUmAmAmUmG*mA*mA
	Antisense strand	eVPmU*fU*mCmAmUfUmAmGmAmAmGmAmAfAmAfG mGmUmGmG*mU*mU
Conjugate 1638	Sense strand	GalNAc(A4GN)*mC*mCmAmCmCmUmUfUfUfCmUmUm CmUmAmAmUmG*mA*mA
	Antisense strand	eVPmU*fU*mCmAmUfUmAmGmAmAmGmAmAfAmAfG mGmUmGmG*mU*mU
Conjugate 1642	Sense strand	GalNAc(Ser1)*mC*mCmAmCmCmUmUfUfUfCmUmUmC mUmAmAmUmGmAmA*GalNAc(Ser1)
	Antisense strand	eVPmU*fU*mCmAmUfUmAmGmAmAmGmAmAfAmAfG mGmUmGmG*mU*mU

wherein, m indicates that the nucleotide adjacent to the right of the identifier m is a 2'-methoxynucleotide; f indicates that the nucleotide adjacent to the right of the identifier f is a 2'-fluoronucleotide; d indicates that the nucleotide adjacent to the right of the identifier d is a 2'-deoxynucleotide; the identifier * indicates that the linkage between two the nucleotides (or between the nucleotide and the delivery carrier moiety) adjacent to the identifier * on the left and right is a phosphorothioate linkage; eVP indicates that the nucleotide adjacent to it on the right is a (*E*)-vinyl phosphate-modified nucleotide; iab indicates an inverted abasic residue;

GalNAc(L96), having the following structure:



.

GalNAc(A1GN), having the following structure:



GalNAc(A2GN), having the following structure:



GalNAc(A3GN), having the following structure:



GalNAc(A4GN), having the following structure:



GalNAc(Ser1), having the following structure:



.

13. A pharmaceutical composition, wherein the pharmaceutical composition comprises the siRNA according to any one of claims 1 to 8 and/or the siRNA conjugate according to any one of claims 9 to 12, and a pharmaceutically acceptable carrier.

14. Use of the siRNA according to any one of claims 1 to 8 and/or the siRNA conjugate according to any one of claims 9 to 12 and/or the pharmaceutical composition according to claim 13 in the manufacture of a medicament for treating and/or preventing a pathological condition or disease associated with AGT gene overexpression.

15. The use according to claim 14, wherein the pathological condition or disease is a disease associated with abnormal blood pressure.